A biotechnology company focused on developing cannabinoid-based prescription medicines derived from cannabis. Its lead product, Epidiolex, received regulatory approvals in the U.S. and Europe for certain rare forms of epilepsy, marking one of the first FDA‑approved plant‑derived cannabinoid therapie...
No congressional trades have been disclosed for gW Pharmaceuticals Plc (GWPH) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
No congressional trades found for this stock.